Osteosarcomas of the mandible

Multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, rare cancer network, GETTEC/refcor and sfce

J. Thariat, T. Schouman, A. Brouchet, J. Sarini, R. C. Miller, H. Reychler, I. Ray-Coquard, A. Italiano, C. Verite, S. Sohawon, E. Bompas, O. Dassonville, S. Salas, K. Aldabbagh, P. Maingon, T. de la MotteRouge, J. E. Kurtz, J. Usseglio, P. Kerbrat, G. Raoul & 9 others J. P. Lotz, G. Bar-Sela, L. Brugières, L. Chaigneau, E. Saada, G. Odin, P. Y. Marcy, A. Thyss, M. Julieron

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Mandibular osteosarcomas (MOS) mostly affect young adults. Their treatment is extrapolated from that of extragnathic osteosarcomas. Material and methods: A retrospective multicooperative group study was conducted to determine the impact of chemotherapy, adjuvant radiation therapy and surgery on outcomes and to identify prognostic factors. This ethical committee-approved study included a centralized review of histology slides and operative reports. Results: Of 111 patients, 58.6% were male, median age 35 years (13%, ≤18 years). Histology was osteoblastic, chondroblastic, fibroblastic, conventional not otherwise specified and others in 39.6%, 30.6%, 8.1%, 12.6% and 8.0%, respectively. Pathological World Health Organisation grades were low, intermediate and high grade in 6.4%, 11.8% and 81.8%, respectively. Surgery was carried out for 94.5% of patients. Neoadjuvant chemotherapy (mixed protocols) was carried out in 93.1% of patients. Postoperative chemotherapy and radiotherapy were carried out in 54.7% and 23.8%, respectively. Median follow-up was 59.6 months (range). Five-year local control, metastasis-free, disease-free and overall survival rates were 64.6%, 68.9%, 53.2% and 69.2%, respectively. Survival was significantly associated with age, tumor size and surgery. Wide surgery with clear margins and free flap reconstruction was the strongest prognostic factor. Neoadjuvant chemotherapy improved disease-free and metastatic-free survival and increased clear margins rates from 50% to 68%. Intermediate grades behaved like high grades in terms of metastatic-free and disease-free survival.Conclusion: This homogeneous series is the largest to date and emphasizes the major impact of clear margins and multidisciplinary management. Neoadjuvant chemotherapy improves disease-free survival and should be recommended for both high and intermediate grade MOS.

Original languageEnglish (US)
Article numbermds507
Pages (from-to)824-831
Number of pages8
JournalAnnals of Oncology
Volume24
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Osteosarcoma
Mandible
Young Adult
Disease-Free Survival
Drug Therapy
Neoplasms
Histology
Radiotherapy
Survival
Free Tissue Flaps
Adjuvant Chemotherapy
Survival Rate
Neoplasm Metastasis
Therapeutics

Keywords

  • Head and neck
  • Jaw
  • Mandible
  • Osteosarcoma
  • Prognostic
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Osteosarcomas of the mandible : Multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, rare cancer network, GETTEC/refcor and sfce. / Thariat, J.; Schouman, T.; Brouchet, A.; Sarini, J.; Miller, R. C.; Reychler, H.; Ray-Coquard, I.; Italiano, A.; Verite, C.; Sohawon, S.; Bompas, E.; Dassonville, O.; Salas, S.; Aldabbagh, K.; Maingon, P.; de la MotteRouge, T.; Kurtz, J. E.; Usseglio, J.; Kerbrat, P.; Raoul, G.; Lotz, J. P.; Bar-Sela, G.; Brugières, L.; Chaigneau, L.; Saada, E.; Odin, G.; Marcy, P. Y.; Thyss, A.; Julieron, M.

In: Annals of Oncology, Vol. 24, No. 3, mds507, 03.2013, p. 824-831.

Research output: Contribution to journalArticle

Thariat, J, Schouman, T, Brouchet, A, Sarini, J, Miller, RC, Reychler, H, Ray-Coquard, I, Italiano, A, Verite, C, Sohawon, S, Bompas, E, Dassonville, O, Salas, S, Aldabbagh, K, Maingon, P, de la MotteRouge, T, Kurtz, JE, Usseglio, J, Kerbrat, P, Raoul, G, Lotz, JP, Bar-Sela, G, Brugières, L, Chaigneau, L, Saada, E, Odin, G, Marcy, PY, Thyss, A & Julieron, M 2013, 'Osteosarcomas of the mandible: Multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, rare cancer network, GETTEC/refcor and sfce', Annals of Oncology, vol. 24, no. 3, mds507, pp. 824-831. https://doi.org/10.1093/annonc/mds507
Thariat, J. ; Schouman, T. ; Brouchet, A. ; Sarini, J. ; Miller, R. C. ; Reychler, H. ; Ray-Coquard, I. ; Italiano, A. ; Verite, C. ; Sohawon, S. ; Bompas, E. ; Dassonville, O. ; Salas, S. ; Aldabbagh, K. ; Maingon, P. ; de la MotteRouge, T. ; Kurtz, J. E. ; Usseglio, J. ; Kerbrat, P. ; Raoul, G. ; Lotz, J. P. ; Bar-Sela, G. ; Brugières, L. ; Chaigneau, L. ; Saada, E. ; Odin, G. ; Marcy, P. Y. ; Thyss, A. ; Julieron, M. / Osteosarcomas of the mandible : Multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, rare cancer network, GETTEC/refcor and sfce. In: Annals of Oncology. 2013 ; Vol. 24, No. 3. pp. 824-831.
@article{cdc60f30ed2a49e3844db66c33f1209f,
title = "Osteosarcomas of the mandible: Multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, rare cancer network, GETTEC/refcor and sfce",
abstract = "Background: Mandibular osteosarcomas (MOS) mostly affect young adults. Their treatment is extrapolated from that of extragnathic osteosarcomas. Material and methods: A retrospective multicooperative group study was conducted to determine the impact of chemotherapy, adjuvant radiation therapy and surgery on outcomes and to identify prognostic factors. This ethical committee-approved study included a centralized review of histology slides and operative reports. Results: Of 111 patients, 58.6{\%} were male, median age 35 years (13{\%}, ≤18 years). Histology was osteoblastic, chondroblastic, fibroblastic, conventional not otherwise specified and others in 39.6{\%}, 30.6{\%}, 8.1{\%}, 12.6{\%} and 8.0{\%}, respectively. Pathological World Health Organisation grades were low, intermediate and high grade in 6.4{\%}, 11.8{\%} and 81.8{\%}, respectively. Surgery was carried out for 94.5{\%} of patients. Neoadjuvant chemotherapy (mixed protocols) was carried out in 93.1{\%} of patients. Postoperative chemotherapy and radiotherapy were carried out in 54.7{\%} and 23.8{\%}, respectively. Median follow-up was 59.6 months (range). Five-year local control, metastasis-free, disease-free and overall survival rates were 64.6{\%}, 68.9{\%}, 53.2{\%} and 69.2{\%}, respectively. Survival was significantly associated with age, tumor size and surgery. Wide surgery with clear margins and free flap reconstruction was the strongest prognostic factor. Neoadjuvant chemotherapy improved disease-free and metastatic-free survival and increased clear margins rates from 50{\%} to 68{\%}. Intermediate grades behaved like high grades in terms of metastatic-free and disease-free survival.Conclusion: This homogeneous series is the largest to date and emphasizes the major impact of clear margins and multidisciplinary management. Neoadjuvant chemotherapy improves disease-free survival and should be recommended for both high and intermediate grade MOS.",
keywords = "Head and neck, Jaw, Mandible, Osteosarcoma, Prognostic, Treatment",
author = "J. Thariat and T. Schouman and A. Brouchet and J. Sarini and Miller, {R. C.} and H. Reychler and I. Ray-Coquard and A. Italiano and C. Verite and S. Sohawon and E. Bompas and O. Dassonville and S. Salas and K. Aldabbagh and P. Maingon and {de la MotteRouge}, T. and Kurtz, {J. E.} and J. Usseglio and P. Kerbrat and G. Raoul and Lotz, {J. P.} and G. Bar-Sela and L. Brugi{\`e}res and L. Chaigneau and E. Saada and G. Odin and Marcy, {P. Y.} and A. Thyss and M. Julieron",
year = "2013",
month = "3",
doi = "10.1093/annonc/mds507",
language = "English (US)",
volume = "24",
pages = "824--831",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Osteosarcomas of the mandible

T2 - Multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, rare cancer network, GETTEC/refcor and sfce

AU - Thariat, J.

AU - Schouman, T.

AU - Brouchet, A.

AU - Sarini, J.

AU - Miller, R. C.

AU - Reychler, H.

AU - Ray-Coquard, I.

AU - Italiano, A.

AU - Verite, C.

AU - Sohawon, S.

AU - Bompas, E.

AU - Dassonville, O.

AU - Salas, S.

AU - Aldabbagh, K.

AU - Maingon, P.

AU - de la MotteRouge, T.

AU - Kurtz, J. E.

AU - Usseglio, J.

AU - Kerbrat, P.

AU - Raoul, G.

AU - Lotz, J. P.

AU - Bar-Sela, G.

AU - Brugières, L.

AU - Chaigneau, L.

AU - Saada, E.

AU - Odin, G.

AU - Marcy, P. Y.

AU - Thyss, A.

AU - Julieron, M.

PY - 2013/3

Y1 - 2013/3

N2 - Background: Mandibular osteosarcomas (MOS) mostly affect young adults. Their treatment is extrapolated from that of extragnathic osteosarcomas. Material and methods: A retrospective multicooperative group study was conducted to determine the impact of chemotherapy, adjuvant radiation therapy and surgery on outcomes and to identify prognostic factors. This ethical committee-approved study included a centralized review of histology slides and operative reports. Results: Of 111 patients, 58.6% were male, median age 35 years (13%, ≤18 years). Histology was osteoblastic, chondroblastic, fibroblastic, conventional not otherwise specified and others in 39.6%, 30.6%, 8.1%, 12.6% and 8.0%, respectively. Pathological World Health Organisation grades were low, intermediate and high grade in 6.4%, 11.8% and 81.8%, respectively. Surgery was carried out for 94.5% of patients. Neoadjuvant chemotherapy (mixed protocols) was carried out in 93.1% of patients. Postoperative chemotherapy and radiotherapy were carried out in 54.7% and 23.8%, respectively. Median follow-up was 59.6 months (range). Five-year local control, metastasis-free, disease-free and overall survival rates were 64.6%, 68.9%, 53.2% and 69.2%, respectively. Survival was significantly associated with age, tumor size and surgery. Wide surgery with clear margins and free flap reconstruction was the strongest prognostic factor. Neoadjuvant chemotherapy improved disease-free and metastatic-free survival and increased clear margins rates from 50% to 68%. Intermediate grades behaved like high grades in terms of metastatic-free and disease-free survival.Conclusion: This homogeneous series is the largest to date and emphasizes the major impact of clear margins and multidisciplinary management. Neoadjuvant chemotherapy improves disease-free survival and should be recommended for both high and intermediate grade MOS.

AB - Background: Mandibular osteosarcomas (MOS) mostly affect young adults. Their treatment is extrapolated from that of extragnathic osteosarcomas. Material and methods: A retrospective multicooperative group study was conducted to determine the impact of chemotherapy, adjuvant radiation therapy and surgery on outcomes and to identify prognostic factors. This ethical committee-approved study included a centralized review of histology slides and operative reports. Results: Of 111 patients, 58.6% were male, median age 35 years (13%, ≤18 years). Histology was osteoblastic, chondroblastic, fibroblastic, conventional not otherwise specified and others in 39.6%, 30.6%, 8.1%, 12.6% and 8.0%, respectively. Pathological World Health Organisation grades were low, intermediate and high grade in 6.4%, 11.8% and 81.8%, respectively. Surgery was carried out for 94.5% of patients. Neoadjuvant chemotherapy (mixed protocols) was carried out in 93.1% of patients. Postoperative chemotherapy and radiotherapy were carried out in 54.7% and 23.8%, respectively. Median follow-up was 59.6 months (range). Five-year local control, metastasis-free, disease-free and overall survival rates were 64.6%, 68.9%, 53.2% and 69.2%, respectively. Survival was significantly associated with age, tumor size and surgery. Wide surgery with clear margins and free flap reconstruction was the strongest prognostic factor. Neoadjuvant chemotherapy improved disease-free and metastatic-free survival and increased clear margins rates from 50% to 68%. Intermediate grades behaved like high grades in terms of metastatic-free and disease-free survival.Conclusion: This homogeneous series is the largest to date and emphasizes the major impact of clear margins and multidisciplinary management. Neoadjuvant chemotherapy improves disease-free survival and should be recommended for both high and intermediate grade MOS.

KW - Head and neck

KW - Jaw

KW - Mandible

KW - Osteosarcoma

KW - Prognostic

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84874580869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874580869&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds507

DO - 10.1093/annonc/mds507

M3 - Article

VL - 24

SP - 824

EP - 831

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

M1 - mds507

ER -